Article thumbnail
Location of Repository

Functional Copy-Number Alterations in Cancer

By Barry S. Taylor, Jordi Barretina, Nicholas D. Socci, Penelope DeCarolis, Marc Ladanyi, Matthew Meyerson, Samuel Singer and Chris Sander


Understanding the molecular basis of cancer requires characterization of its genetic defects. DNA microarray technologies can provide detailed raw data about chromosomal aberrations in tumor samples. Computational analysis is needed (1) to deduce from raw array data actual amplification or deletion events for chromosomal fragments and (2) to distinguish causal chromosomal alterations from functionally neutral ones. We present a comprehensive computational approach, RAE, designed to robustly map chromosomal alterations in tumor samples and assess their functional importance in cancer. To demonstrate the methodology, we experimentally profile copy number changes in a clinically aggressive subtype of soft-tissue sarcoma, pleomorphic liposarcoma, and computationally derive a portrait of candidate oncogenic alterations and their target genes. Many affected genes are known to be involved in sarcomagenesis; others are novel, including mediators of adipocyte differentiation, and may include valuable therapeutic targets. Taken together, we present a statistically robust methodology applicable to high-resolution genomic data to assess the extent and function of copy-number alterations in cancer

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2004). A census of human cancer genes.
  2. (2005). A comparison study: applying segmentation to array CGH data for downstream analyses.
  3. (2005). A fine-scale map of recombination rates and hotspots across the human genome.
  4. (2007). A second generation human haplotype map of over 3.1 million SNPs.
  5. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
  6. (1997). Adenoviral E1A-associated protein p300 is involved in acute myeloid leukemia with t(11;22)(q23;q13).
  7. (2006). Adipocyte differentiation from the inside out.
  8. (1995). Allelotype of pancreatic adenocarcinoma using xenograft enrichment.
  9. (2005). Array comparative genomic hybridization and its applications in cancer.
  10. (2007). Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma.
  11. (2007). Assessing the significance of conserved genomic aberrations using high resolution genomic microarrays.
  12. (1997). Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk.
  13. (2007). Characterizing the cancer genome in lung adenocarcinoma.
  14. (2003). Chromosome aberrations in solid tumors.
  15. (2004). Circular binary segmentation for the analysis of array-based DNA copy number data.
  16. (2007). Comment on ‘‘The consensus coding sequences of human breast and colorectal cancers’’.
  17. (2007). Comment on ‘‘The consensus coding sequences of human breast and colorectal cancers’’. Science 317: 1500; author reply 1500.
  18. (2005). Comparative analysis of algorithms for identifying amplifications and deletions in array CGH data.
  19. (1995). Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing.
  20. (2006). Copy number variation: new insights in genome diversity.
  21. (2008). Cytogenetic and Molecular Genetic Pathology of Soft Tissue Tumors. In: Enzinger & Weiss’s Soft Tissue Tumors;
  22. (2004). Detection of large-scale variation in the human genome.
  23. (2002). Distinct chromosomal imbalances in pleomorphic and in high-grade dedifferentiated liposarcomas.
  24. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
  25. (2004). EGF receptor gene mutations are common in lung cancers from ‘‘never smokers’’ and are associated with sensitivity of tumors to gefitinib and erlotinib.
  26. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
  27. (2002). Epigenetic versus genetic alterations in the inactivation of Ecadherin. Semin Cancer Biol 12: 373–379.
  28. (2007). From microscopes to microarrays: dissecting recurrent chromosomal rearrangements.
  29. (2007). Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma.
  30. (2007). Genomic mutation consequence calculator.
  31. (2006). Global variation in copy number in the human genome.
  32. (2006). HFM1, the human homologue of yeast Mer3, encodes a putative DNA helicase expressed specifically in germ-line cells.
  33. (2004). High-resolution characterization of the pancreatic adenocarcinoma genome.
  34. (2008). High-Resolution Mapping of Crossovers Reveals Extensive Variation in Fine-Scale Recombination Patterns Among Humans.
  35. (2006). Highresolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients.
  36. (2005). Highresolution genomic profiles of human lung cancer.
  37. (2004). Hotspots of homologous recombination in the human genome: not all homologous sequences are equal.
  38. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene.
  39. (2005). Increased expression of delta-catenin/neural plakophilin-related armadillo protein is associated with the down-regulation and redistribution of E-cadherin and p120ctn in human prostate cancer.
  40. (2004). Large-scale copy number polymorphism in the human genome.
  41. (2000). Loss-of-heterozygosity analysis of small-cell lung carcinomas using singlenucleotide polymorphism arrays.
  42. (2000). Malignant peripheral nerve sheath tumors in neurofibromatosis 1.
  43. (2003). Mechanisms of sarcoma development.
  44. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
  45. (2002). Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma.
  46. (2007). Modeling recurrent DNA copy number alterations in array CGH data.
  47. (2002). Molecular mechanisms for genomic disorders.
  48. (2007). Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
  49. (2002). Overexpression and ribozyme-mediated targeting of transcriptional coactivators CREB-binding protein and p300 revealed their indispensable roles in adipocyte differentiation through the regulation of peroxisome proliferator-activated receptor gamma.
  50. (2007). Patterns of somatic mutation in human cancer genomes.
  51. (1995). Sarcomas and other malignancies of soft tissue, retroperitoneum, peritoneum, pleura, heart, mediastinum, and spleen.
  52. (2006). STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments.
  53. (2006). Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk.
  54. (2007). The Cancer Genome Atlas.
  55. (2006). The consensus coding sequences of human breast and colorectal cancers.
  56. (2004). The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website.
  57. (2008). The fine-scale and complex architecture of human copy-number variation.
  58. (2004). The fine-scale structure of recombination rate variation in the human genome.
  59. (2007). The Genomic Landscapes of Human Breast and Colorectal Cancers.
  60. (2005). Wnt5b partially inhibits canonical Wnt/beta-catenin signaling pathway and promotes adipogenesis in 3T3–L1 preadipocytes.
  61. (2002). World Health Organization, International Academy of Pathology

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.